Aromatase inhibitors in women with clomiphene citrate resistance: a randomized, double-blind, placebo-controlled trial

Abstract

In 36 women with polycystic ovary syndrome and clomiphene citrate resistance, letrozole, an aromatase inhibitor, statistically significantly increased the ovulation rate by 33.3% in the treatment group, indicating that letrozole can be used as an effective and simple alternate ovulation-inducing agent in these women.